Matthew Perry
Direktor/Vorstandsmitglied bei
XOMA ROYALTY CORPORATION
Vermögen: 1 Mio $ am 31.05.2026
Profil
Matthew D.
Perry is the founder of Nordic Biotech Advisors ApS.
Current jobs include Independent Director at XOMA Royalty Corp.
since 2017, President at Biotechnology Value Fund LP, and Managing Partner at Coastlands Capital LP starting in 2025.
Former jobs include Independent Non-Executive Director at CTI BioPharma Corp.
from 2016 to 2023, President & Director at BVF, Inc., Director at Ziarco Pharma Ltd., President & Portfolio Manager at BVF Partners LP, and Account Executive at Feinstein Kean Partners, Inc. and Feinstein Kean Healthcare from 1994 to 1996.
Education includes an undergraduate degree from The College of William & Mary, conferred in 1994.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
XOMA ROYALTY CORPORATION 0,22 % | 21.05.2026 | 27.426 ( 0,22 % ) | 1 Mio $ | 31.05.2026 |
Aktive Positionen von Matthew Perry
| Unternehmen | Position | Beginn |
|---|---|---|
| XOMA ROYALTY CORPORATION | Direktor/Vorstandsmitglied | 16.02.2017 |
Nordic Biotech Advisors ApS
 Nordic Biotech Advisors ApS Investment ManagersFinance NB Capital is an active manager which provides financing for pre-seed, seed, later, and growth-stage capital requirements, and invests in both public and private companies. The firm invests in young and established companies operating in the health technology sector, and industries such as biotechnology and pharmaceuticals. NB Capital invests in companies located in Denmark, Northern Europe, and North America, and looks to take minority stake positions in its investments, as well as a seat on the board. | Gründer | - |
Biotechnology Value Fund LP
 Biotechnology Value Fund LP Investment Trusts/Mutual FundsMiscellaneous Functions as a hedge fund | Präsident | - |
Ehemalige bekannte Positionen von Matthew Perry
| Unternehmen | Position | Ende |
|---|---|---|
| CTI BIOPHARMA CORP. | Direktor/Vorstandsmitglied | 23.06.2023 |
Feinstein Kean Partners, Inc.
 Feinstein Kean Partners, Inc. Miscellaneous Commercial ServicesCommercial Services Public relations firm | Corporate Officer/Principal | 01.12.1996 |
Feinstein Kean Healthcare
 Feinstein Kean Healthcare Miscellaneous Commercial ServicesCommercial Services Provides strategic communications consulting services | Corporate Officer/Principal | 01.01.1996 |
Ziarco Pharma Ltd.
 Ziarco Pharma Ltd. BiotechnologyHealth Technology Provides therapeutics targeting inflammatory and allergic diseases | Direktor/Vorstandsmitglied | - |
BVF Partners LP
 BVF Partners LP Investment ManagersFinance BVF generally pursues value-oriented investment strategies, investing primarily in the marketable securities issued by biotechnology companies. The focus of the BVF strategy is on fundamental, bottom-up analysis of individual issuers based on the theory that market mispricing exist because market prices do not incorporate all knowable economic and other relevant data. | Präsident | - |
Ausbildung von Matthew Perry
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
60
Beziehungen ersten Grades
10
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 10 |
|---|---|
Biotechnology Value Fund LP
Biotechnology Value Fund LP Investment Trusts/Mutual FundsMiscellaneous Functions as a hedge fund | Miscellaneous |
CTI BioPharma Corp.
 CTI BioPharma Corp. Pharmaceuticals: MajorHealth Technology Engages in acquisition, development and commercialization of novel targeted therapies for blood-related cancers | Health Technology |
XOMA Royalty Corp.
 XOMA Royalty Corp. Pharmaceuticals: MajorHealth Technology Discovers and develops antibody therapeutics | Health Technology |
BVF, Inc.
 BVF, Inc. Investment Banks/BrokersFinance Manages hedge funds and engages in investment business | Finance |
BVF Partners LP
BVF Partners LP Investment ManagersFinance BVF generally pursues value-oriented investment strategies, investing primarily in the marketable securities issued by biotechnology companies. The focus of the BVF strategy is on fundamental, bottom-up analysis of individual issuers based on the theory that market mispricing exist because market prices do not incorporate all knowable economic and other relevant data. | Finance |
Feinstein Kean Partners, Inc.
Feinstein Kean Partners, Inc. Miscellaneous Commercial ServicesCommercial Services Public relations firm | Commercial Services |
The College of William & Mary
 The College of William & Mary Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nordic Biotech Advisors ApS
Nordic Biotech Advisors ApS Investment ManagersFinance NB Capital is an active manager which provides financing for pre-seed, seed, later, and growth-stage capital requirements, and invests in both public and private companies. The firm invests in young and established companies operating in the health technology sector, and industries such as biotechnology and pharmaceuticals. NB Capital invests in companies located in Denmark, Northern Europe, and North America, and looks to take minority stake positions in its investments, as well as a seat on the board. | Finance |
Feinstein Kean Healthcare
Feinstein Kean Healthcare Miscellaneous Commercial ServicesCommercial Services Provides strategic communications consulting services | Commercial Services |
Ziarco Pharma Ltd.
Ziarco Pharma Ltd. BiotechnologyHealth Technology Provides therapeutics targeting inflammatory and allergic diseases | Health Technology |
